Status:
COMPLETED
Thromboelastographic Methods in Deciding Therapy on Moderate to Severe COVID-19 Patients
Lead Sponsor:
Indonesia University
Conditions:
COVID-19
Eligibility:
All Genders
19+ years
Brief Summary
This study is a prospective observational study that compares the anticoagulant therapy decision time among moderate and severe COVID-19 patients whose coagulation profiles were tested with thromboela...
Detailed Description
A prospective observational study was conducted among moderate to severe COVID-19 patients in the High Care Unit and Intensive Care Unit at Kiara Ultimate, Cipto Mangunkusumo Hospital, Indonesia. We c...
Eligibility Criteria
Inclusion
- 1\. Confirmed COVID-19 (Positive SARS-CoV-2 PCR test), 3. Moderate or severe symptoms (We defined moderate COVID-19 as patients with clinical signs of pneumonia with SpO2 \>93% in room air and severe COVID-19 as pneumonia with SpO2 ≤93% in room air or ventilator support requirement), and 4. The family signed the informed consent
Exclusion
- History of blood clotting disorders (eg, hemophilia and Von Willebrand's disease),
- Have contraindications to the administration of anticoagulants, for example:
- Platelet count \< 25,000
- Has bleeding manifestations
- History of heparin allergy or heparin-induced thrombocytopenia
- Pregnant
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 9 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05343728
Start Date
October 1 2020
End Date
July 9 2021
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusumo Cental National Hospital
Jakarta, DKI Jakarta, Indonesia, 10430